ARIH1 and breast cancer: Given that paclitaxel exhibited a greater microtubule-stabilizing effect in ARIH1-deficient cells, we hypothesized that breast cancer cells lacking ARIH1 would demonstrate increased sensitivity and responsiveness to the cytotoxic effects of paclitaxel.